← All trials
NCT01259531
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2010
- Primary completion
- Sep 1, 2011
- Completion date
- Sep 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- JW PharmaceuticalLead sponsor
- Sungkyunkwan UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Hallym UniversityCollaborator
- Chonnam National UniversityCollaborator
- Sungkyunkwan UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yeungnam UniversityCollaborator
- Korea UniversityCollaborator
- Seoul National UniversityCollaborator
- University of UlsanCollaborator
- University of UlsanOverall official - principal investigator
- Chonbuk National UniversityCollaborator
- Chonnam National UniversityStudy chair
- Hallym UniversityOverall official - principal investigator
- Yeongnam UniversityOverall official - principal investigator
- Chungbuk National UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.